Cyclerion Therapeutics Inc
CYCN
NASDAQ
Biotechnology
$3.79
USD
-0.12 (-3.07%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $18.54M
Volume 24.2K
Revenue
$1.90M
TTM
-12.6%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-6.71M
TTM
-244.7%
YoY
Operating Cash Flow
$-4.45M
TTM
-57.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.1 | 0.9 | 1.0 | 0.0 | 0.0 |
YoY Growth | — | +351.0% | -43.2% | -100.0% | -100.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.1 | 0.9 | 1.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.7 | 1.5 | 1.3 | 2.5 | 1.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 1.8 | 1.9 | 1.9 | 3.2 | 1.8 |
Operating Income | -1.7 | -1.0 | -0.8 | -3.2 | -1.8 |
EBITDA | -1.7 | -1.0 | -0.8 | -3.2 | -1.8 |
Other Income / Expense | 1.3 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 1.3 | 0.0 | 0.0 | 0.0 | 0.0 |
Income Before Income Taxes | -0.3 | -1.0 | -0.8 | -3.2 | -1.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -0.3 | -1.0 | -0.8 | -3.2 | -1.8 |
Consolidated Net Income / Loss | -0.3 | -1.0 | -0.8 | -3.2 | -1.8 |
Net Income Attributable to Common Shareholders | -0.3 | -1.0 | -0.8 | -3.2 | -1.8 |
Basic EPS | -$0.11 | -$0.30 | -$0.21 | -$0.76 | -$0.41 |
Diluted EPS | -$0.11 | -$0.30 | -$0.21 | -$0.76 | -$0.41 |
Basic Shares Outstanding | 3.1M | 3.2M | 3.9M | 4.2M | 4.3M |
Diluted Shares Outstanding | 3.1M | 3.2M | 3.9M | 4.2M | 4.3M |